Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
More News: Aspirin | Clopidogrel | Coumadin | Databases & Libraries | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Endocrinology | Japan Health | Plavix | Pradaxa | Study | Warfarin